首页/数据集/Immune activation and inflammation biomarker change from baseline to week 24/28.

Immune activation and inflammation biomarker change from baseline to week 24/28.

Figshare2017-06-13 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/Immune_activation_and_inflammation_biomarker_change_from_baseline_to_week_24_28_/5101750 数据链接链接失效反馈

官方服务：

资源简介：

Immune activation and inflammation biomarker change from baseline to week 24/28.

应用场景：

创建时间：

2017-06-13

多发性硬化症临床试验

临床疗效评估

RRF = Rate of relapse free patients after 2 years, SE = Standard error, ARR = Annualized relapse rate over 2 years, SD = Standard deviation, 2001/2005 indicates the use of the original 2001 McDonald c

Figshare2015-12-02 更新50

Supplementary Material for: A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression

肿瘤免疫治疗

临床疗效评估

Introduction: In a multicenter, open-label, parallel-group, randomized, phase 2 study for pretreated advanced hepatocellular carcinoma (HCC), camrelizumab showed potent antitumor activity and acceptab

NIAID Data Ecosystem50

Quality health indicators achieved over the first 12 months of observation, stratified by treatment allocation (N = 818).

临床疗效评估

医疗质量指标

Quality health indicators achieved over the first 12 months of observation, stratified by treatment allocation (N = 818).

Figshare2022-11-02 更新30

COR peak week 1 improvement and COR peak week 5 improvement.

抗抑郁药物疗效

临床疗效评估

Response and remission rates after 5 weeks of treatment in 40 depressed patients (sample 2) treated with either reboxetine (n = 20) or mirtazapine (n = 20) [33]. Patients are subdivided into COR peak

NIAID Data Ecosystem50

An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer

结直肠癌辅助化疗

临床疗效评估

This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from

NIAID Data Ecosystem40

Immune activation and inflammation biomarker change from baseline to week 24/28.

资源简介：

相关数据集